RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Kiadis Pharma Stock

Kiadis Pharma Equity 2024

Kiadis Pharma Equity

0 EUR

Ticker

KDS.AS

ISIN

NL0011323407

WKN

A14VE3

In 2024, Kiadis Pharma's equity was 0 EUR, a 0% increase from the 0 EUR equity in the previous year.

Kiadis Pharma Aktienanalyse

What does Kiadis Pharma do?

Kiadis Pharma NV was founded in 1997 in Amsterdam and is an innovative biotechnology company specializing in the development of cell therapies for the treatment of blood cancer diseases. The company is based in the Netherlands and is listed on the Euronext Amsterdam stock exchange. The business model of Kiadis is based on the development of therapies for patients with high medical needs, especially for individuals with severe blood cancer diseases for which there are no cure options. The company employs a proprietary platform technology that is based on the activation of T-cells for the therapy of cancer patients. Kiadis is currently developing various therapeutic approaches for the treatment of blood cancer diseases such as leukemia, lymphoma, and multiple myeloma. The company's main products are ATIR101 and ATIR201. ATIR101 is a cell therapy for patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) who require an allogeneic stem cell transplant. This therapy aims to reduce the risk of transplant rejection and graft-versus-host disease (GVHD), thereby increasing patients' chances of survival. ATIR201 is a therapy for the treatment of patients with multiple myeloma who require an allogeneic stem cell transplant. This therapy aims to reduce the risks of transplant rejection and GVHD, thereby increasing patients' chances of survival. Kiadis has also developed another platform technology called CytoSen, which is based on the activation of NK cells for the immunotherapy of cancer. The CytoSen technology aims to enhance the effectiveness of T-cell therapy by combining it with NK cells. Kiadis is continuously working to improve and expand its products and therapies. The company has a strong pipeline of product candidates at various stages of development targeting the treatment of leukemia, lymphoma, multiple myeloma, and other cancer diseases. The company has also entered into a partnership with Sanofi to accelerate the development of its therapies. Overall, Kiadis Pharma NV has an impressive history as an innovative company with a clear focus on the development of cell therapies for the treatment of blood cancer diseases. The company is dedicated to improving the lives of cancer patients and continuously works on the development of new therapies to improve the chances of survival and quality of life for cancer patients worldwide. Kiadis Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Kiadis Pharma's Equity

Kiadis Pharma's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Kiadis Pharma's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Kiadis Pharma's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Kiadis Pharma's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Kiadis Pharma’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Kiadis Pharma stock

What is the equity of Kiadis Pharma this year?

Kiadis Pharma has equity of 0 EUR this year.

What was the equity of Kiadis Pharma compared to the previous year?

The equity of Kiadis Pharma has increased/decreased by 0% decreased compared to the previous year.

What impact does a high equity have on investors of Kiadis Pharma?

A high equity is advantageous for investors of Kiadis Pharma as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Kiadis Pharma?

A low equity can be a risk for investors of Kiadis Pharma, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Kiadis Pharma affect the company?

An increase in equity of Kiadis Pharma can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Kiadis Pharma affect the company?

A reduction in equity of Kiadis Pharma can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Kiadis Pharma?

Some factors that can affect the equity of Kiadis Pharma include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Kiadis Pharma so important for investors?

The equity of Kiadis Pharma is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Kiadis Pharma take to change the equity?

To change equity, Kiadis Pharma can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Kiadis Pharma pay?

Over the past 12 months, Kiadis Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Kiadis Pharma is expected to pay a dividend of 0 EUR.

What is the dividend yield of Kiadis Pharma?

The current dividend yield of Kiadis Pharma is .

When does Kiadis Pharma pay dividends?

Kiadis Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Kiadis Pharma?

Kiadis Pharma paid dividends every year for the past 0 years.

What is the dividend of Kiadis Pharma?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Kiadis Pharma located?

Kiadis Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kiadis Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kiadis Pharma from 12/19/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 12/19/2024.

When did Kiadis Pharma pay the last dividend?

The last dividend was paid out on 12/19/2024.

What was the dividend of Kiadis Pharma in the year 2023?

In the year 2023, Kiadis Pharma distributed 0 EUR as dividends.

In which currency does Kiadis Pharma pay out the dividend?

The dividends of Kiadis Pharma are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Kiadis Pharma stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Kiadis Pharma

Our stock analysis for Kiadis Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kiadis Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.